Log In
Print this Print this

Biosimilar trastuzumab (AP063)

  Manage Alerts
Collapse Summary General Information
Company Aprogen Inc.
DescriptionBiosimilar of trastuzumab, a humanized mAb against epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionBinds HER2/neu; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBreast cancer
Indication DetailsTreat breast cancer
Regulatory Designation
PartnerNichi-Iko Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today